Cancer Cells in 3D

Dr. Alan Nelson shares with Discovery Series members how new lung cell screening technology will enable early detection of the #1 cancer killer worldwide.

The exciting 2006-2007 season of the Science & Technology Discovery Series continued on Friday, October 13th in Seattle with a presentation by Dr. Alan Nelson, chairman and CEO of VisionGate, Inc. Dr. Nelson explained how VisionGate’s LuCED (Lung Cancer Early Detection) test can be used for regular, cost-effective screening of high-risk patients using the company’s unique Cell-CT platform. This new technology uses hundreds of three-dimensional images of cells to accurately determine the likelihood of a patient having early stage lung cancer, enabling earlier diagnosis and intervention and saving lives that otherwise would be lost to this killer disease.

Did you know...?

• More than 162,000 Americans will die of lung cancer this year, and 21 million are deemed to be at “high risk” of developing the disease. An estimated one million new cases worldwide are diagnosed each year.
• There is no evidence to suggest that genetics plays a role in determining whether a person may develop lung cancer.
• Most lung cancer cases are not diagnosed until the disease is in the later stages. For those patients who receive an early diagnosis, the 5-year survival rate is greater than 75%.

Dr. Nelson’s PowerPoint presentation is available as a PDF on the Technology Alliance web site.

Science & Technology Discovery Series is sponsored by:
Armfield, Harrison & Thomas, Inc., Perkins Coie, and Swedish Medical Center.